Abstract
42 - A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have